# ALNY · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** ALNY  
**Sources:** 30  
**Published:** 2026-07-30  
**Canonical:** https://app.k3vl4r.com/research/deep-research-alny-catalysts-narrative-risks-593

---

# ALNY (Alnylam Pharmaceuticals) — Research Report as of 2026-08-03

## Summary

ALNY is a leading RNAi therapeutics company that just reported Q2 2026 earnings on July 30, 2026 [[4]](https://investors.alnylam.com/press-release?id=29986). The stock has experienced extreme volatility — plummeting as much as 29% on the earnings day [[2]](https://www.fiercepharma.com/pharma/alnylam-shares-tank-27-amvuttra-disappoints-attr-outlook-cut-2026) — driven by a guidance cut despite a quarter that showed sequential demand acceleration. The stock currently trades around $271.77 [[13]](https://tickzen.app/stocks/alny/forecast), well below analyst consensus targets of ~$434–$439 [[12]](https://vcpscanner.com/stock/alny/price-target)[[13]](https://tickzen.app/stocks/alny/forecast), which may explain why quantitative screens are flagging it tonight as a top scorer: the gap between price and target has widened dramatically following the sell-off.

---

## Recent Catalysts (Last ~1–3 Months)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-alny-catalysts-narrative-risks-593 (free to sign up)._